Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as when compared with imatinib, for the first-line therapy of CML-CP. 5 hundred and nineteen clients with freshly diagnosed CML-CP have been randomly assigned to get dasatinib in a dose of one hundred mg once day by day (259 https://hermannm307ycg0.blognody.com/profile